CSIMarket Company Name, Ticker, Customers, else..
 

Immunic Inc   (NASDAQ: IMUX)
Other Ticker:  
 

Immunic Inc 's

Competitiveness



 
 

IMUX Sales vs. its Competitors Q1 2025


Comparing the current results to its competitors, Immunic Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, despite the revenue increase by the most of its competitors of 169.38 %, recorded in the same quarter.

• List of IMUX Competitors





Revenue Growth Comparisons




Net Income Comparison

Immunic Inc recorded a net loss, as well as most of its competitors.

<<  IMUX Stock Performance Comparisons





*Market share is calculated based on total revenue.





Publicly Traded Peers of Immunic Inc




X4 Pharmaceuticals Inc
Share Performance



 0.00%
30 Days
X4 Pharmaceuticals Inc
Profile

X4 Pharmaceuticals Inc is a biopharmaceutical company focused on the research and development of innovative treatments for rare diseases, particularly those involving the immune system and rare genetic disorders. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials, and ultimately bringing these therapies to market to improve patient outcomes.

More about X4 Pharmaceuticals Inc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.341 mill. $ 31.364 mill. $ 14.598 mill.


Curevac N v
Share Performance



 +56.52%
This Year
Curevac N v
Profile

CureVac N.V. is a biopharmaceutical company focused on developing and manufacturing innovative mRNA-based therapeutics and vaccines. Their business model involves leveraging their proprietary technology platform to develop a diverse pipeline of potential mRNA-based products, from early-stage research to clinical trials. CureVac N.V. collaborates with partners and organizations to advance their product candidates, aiming to address unmet medical needs and improve patient outcomes.

More about Curevac N v 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,192.500 mill. $ 60.209 mill. $ -291.387 mill.


Equillium Inc
Share Performance



 0.00%
30 Days
Equillium Inc
Profile

Equillium Inc operates on a business model that focuses on developing and commercializing novel treatments for immune and inflammatory disorders by leveraging their expertise in immunology and translational science. They aim to address unmet medical needs through the discovery and development of therapies targeting specific immune pathways.

More about Equillium Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 14.946 mill. $ - mill. $ -6.281 mill.


Serina Therapeutics Inc
Share Performance



 -39.93%
One Year
Serina Therapeutics Inc
Profile



More about Serina Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 51.804 mill. $ - mill. $ -16.029 mill.




Sources: Immunic Inc and all companies mentioned above in this report


Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com